Beyond Air Inc
For the period ended Mar 31, 2025. Filed Jun 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 20, 2025
XAIR$2.52+10.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| For The Year Ended March 31, 2025 · For The Year Ended March 31, 2024 | ||||
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net loss | $(48,479) | $(64,295) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 2,999 | 1,775 | ||
| Stock-based compensation | 9,146 | 21,337 | ||
| Amortization of debt discount and accretion of debt issuance costs | 1,028 | 1,150 | ||
| Amortization of licensed right to use technology | 205 | 205 | ||
| Amortization of operating lease assets | 367 | 372 | ||
| Change in fair value of warrant liability | (237) | (611) | ||
| Change in fair value of derivative liability | (1,314) | (48) | ||
| Unrealized (gain)/loss on marketable securities | 60 | 123 | ||
| Provision for inventory losses | 177 | - | ||
| Loss on extinguishment of debt | 2,447 | - | ||
| Impairment of fixed assets | 505 | - | ||
| Loss on disposal of fixed assets | 334 | 15 | ||
| Paid in kind interest | 696 | - | ||
| Changes in: | ||||
| Grant receivable | - | 420 | ||
| Inventory | (466) | (998) | ||
| Accounts receivable | (390) | (319) | ||
| Other current assets and prepaid expenses | 1,048 | (1,583) | ||
| Accounts payable | 399 | (467) | ||
| Accrued expenses | (6,358) | (12,710) | ||
| Operating lease liabilities | (385) | (381) | ||
| Net cash used in operating activities | (38,218) | (56,014) | ||
| Cash flows from investing activities | ||||
| Purchase of marketable securities | (30,878) | (128,770) | ||
| Proceeds from sale of marketable securities | 51,656 | 122,280 | ||
| Security deposits made on operating leases | 10 | - | ||
| Purchase of property and equipment | (5,883) | (5,745) | ||
| Net cash provided by (used in) investing activities | 14,905 | (12,235) | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of common stock through at the market offerings | 2,151 | 13,376 | ||
| Proceeds from the sale of common stock of NeuroNos | 2,000 | - | ||
| Proceeds from issuance of common stock and pre-funded warrants through securities purchase agreement II | 18,858 | - | ||
| Proceeds from issuance of common stock in connection with a purchase agreement | - | 14,591 | ||
| Proceeds from issuance of common stock through exercise of options | - | 217 | ||
| Proceeds from issuance of common stock through exercise of warrants | 365 | - | ||
| Proceeds from long term loan | 11,324 | 15,818 | ||
| Payment of loan | (18,052) | (835) | ||
| Net cash provided by financing activities | 16,646 | 43,167 | ||
| Effect of exchange rate changes on cash and cash equivalents | (45) | (77) | ||
| Decrease in cash, cash equivalents and restricted cash | (6,712) | (25,160) | ||
| Cash, cash equivalents and restricted cash at beginning of year | 11,608 | 36,768 | ||
| Cash, cash equivalents and restricted cash at end of year | $4,896 | $11,608 | ||
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Debt discount | $3,249 | $4,541 | ||
| End of term loan liability | $ | - | $(613) | |
| Warrant liability | $ | - | $(885) | |
| Derivative liability | $ | - | $(1,361) | |
| Short term finance liability | $693 | $740 | ||
| Fixed assets recorded in accounts payable and accrued expenses | $396 | $404 | ||
| Interest paid | $1,197 | $1,759 | ||
| Income taxes paid | $ | - | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.